QLB Biotherapeutics Inc., located in Boston, Massachusetts, is a startup biotechnology company focusing on discovering and developing biological therapeutics. QLB Bio is funded by Qilu Pharmaceutical, and will become its biggest overseas Research and Development Center. QLB Bio is devoted to developing next-generation cancer therapeutics using the transformative potential of immunotherapy. We have an ambitious vision and a growing pipeline of novel cancer immunotherapy biological candidates to treat solid tumors as well as hematologic cancers. To achieve our mission, we seek highly motivated professionals who share our dedication to patients and our passion for discovery, innovation and scientific rigor.
Established in 1958 and headquartered in the City of Jinan, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China with a comprehensive industrial value chain focusing on development, manufacture and marketing of drug substances, drug products and biologics. After years of development and expanding, the company now has 9 manufacturer sites, 13 domestic subsidiaries, 10 overseas subsidiaries and over 14,000 staff worldwide. With a sales revenue of approximately $3.1 billion, Qilu Pharmaceutical products are available in over 70 countries globally.